These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 7592185)
21. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance]. Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699 [TBL] [Abstract][Full Text] [Related]
22. Ex vivo synergy of arachidonate-enriched serum with ceftazidime and amikacin on multidrug-resistant Pseudomonas aeruginosa. Giamarellos-Bourboulis EJ; Plachouras D; Skiathitis S; Raftogiannis M; Dionyssiou-Asteriou A; Dontas I; Karayannacos PE; Giamarellou H J Antimicrob Chemother; 2003 Feb; 51(2):423-6. PubMed ID: 12562715 [TBL] [Abstract][Full Text] [Related]
23. In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa. Bayer AS; Kim KS Chemotherapy; 1986; 32(4):364-73. PubMed ID: 2942342 [TBL] [Abstract][Full Text] [Related]
24. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa. Giamarellos-Bourboulis EJ; Mouktaroudi M; Adamis T; Koussoulas V; Baziaka F; Perrea D; Karayannacos PE; Giamarellou H Antimicrob Agents Chemother; 2004 Dec; 48(12):4713-7. PubMed ID: 15561848 [TBL] [Abstract][Full Text] [Related]
25. In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria. Lim VK; Halijah MY Med J Malaysia; 2001 Sep; 56(3):365-9. PubMed ID: 11732084 [TBL] [Abstract][Full Text] [Related]
27. Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis. Bayer AS; Crowell DJ; Yih J; Bradley DW; Norman DC J Infect Dis; 1988 Aug; 158(2):355-9. PubMed ID: 3042875 [TBL] [Abstract][Full Text] [Related]
28. Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice. Chandrasekar PH; Sluchak JA; Kruse JA Antimicrob Agents Chemother; 1993 Sep; 37(9):1927-30. PubMed ID: 8239607 [TBL] [Abstract][Full Text] [Related]
29. Multidrug-resistant Pseudomonas aeruginosa strains harbouring R-plasmids and AmpC beta-lactamases isolated from hospitalised burn patients in a tertiary care hospital of North India. Shahid M; Malik A; Sheeba FEMS Microbiol Lett; 2003 Nov; 228(2):181-6. PubMed ID: 14638422 [TBL] [Abstract][Full Text] [Related]
30. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Lu Q; Yang J; Liu Z; Gutierrez C; Aymard G; Rouby JJ; Am J Respir Crit Care Med; 2011 Jul; 184(1):106-15. PubMed ID: 21474643 [TBL] [Abstract][Full Text] [Related]
31. Serum bactericidal activity of mezlocillin, ceftazidime, mezlocillin/ceftazidime and mezlocillin/amikacin against Klebsiella pneumoniae and Pseudomonas aeruginosa. Van Laethem Y; Klastersky J Eur J Clin Microbiol; 1986 Feb; 5(1):110-4. PubMed ID: 3084239 [TBL] [Abstract][Full Text] [Related]
33. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. Fantin B; Farinotti R; Thabaut A; Carbon C J Antimicrob Chemother; 1994 Mar; 33(3):563-9. PubMed ID: 8040120 [TBL] [Abstract][Full Text] [Related]
34. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units. Vojtová V; Kolár M; Hricová K; Uvízl R; Neiser J; Blahut L; Urbánek K New Microbiol; 2011 Jul; 34(3):291-8. PubMed ID: 21811750 [TBL] [Abstract][Full Text] [Related]
35. Bactericidal interactions of a beta-lactam and beta-lactamase inhibitors in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive overproducer of type Id beta-lactamase. Bayer AS; Selecky M; Babel K; Hirano L; Yih J; Parr TR Antimicrob Agents Chemother; 1987 Nov; 31(11):1750-5. PubMed ID: 3124738 [TBL] [Abstract][Full Text] [Related]
36. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker AA; Gürler B J Antimicrob Chemother; 1995 Oct; 36(4):707-11. PubMed ID: 8591946 [TBL] [Abstract][Full Text] [Related]
37. Emergence of ciprofloxacin-resistant Pseudomonas aeruginosa after combined therapy with ciprofloxacin and amikacin. Azadian BS; Bendig JW; Samson DM J Antimicrob Chemother; 1986 Dec; 18(6):771. PubMed ID: 3102449 [No Abstract] [Full Text] [Related]
38. Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa. Edgeworth JD; Merante D; Patel S; Young C; Jones P; Vithlani S; Wyncoll D; Roberts P; Jones A; Den Nagata T; Ariyasu M; Livermore DM; Beale R Clin Infect Dis; 2019 May; 68(11):1932-1934. PubMed ID: 30418554 [TBL] [Abstract][Full Text] [Related]
39. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. Oie S; Uematsu T; Sawa A; Mizuno H; Tomita M; Ishida S; Okano Y; Kamiya A J Antimicrob Chemother; 2003 Dec; 52(6):911-4. PubMed ID: 14585851 [TBL] [Abstract][Full Text] [Related]
40. In-vitro study of the activity of ciprofloxacin combined with amikacin or ceftazidime against Pseudomonas aeruginosa. Farrag NN; Bendig JW; Talboys C; Azadian BS J Antimicrob Chemother; 1986 Dec; 18(6):770. PubMed ID: 3102448 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]